Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective
- 1 January 2003
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 31 (2), 99-103
- https://doi.org/10.1038/sj.bmt.1703787
Abstract
Cyclophosphamide with granulocyte colony stimulating factor (G-CSF) is commonly used to mobilize stem cells in multiple myeloma. Timing of collection is variable and incidence and severity of side effects is substantial. To optimize timing of collection, to reduce side effects and to limit costs of the procedure, we evaluated vinorelbine, a drug shown to have activity in multiple myeloma, in combination with G-CSF as mobilizing regimen. A total of 19 consecutive patients with advanced stage multiple myeloma received one dose of vinorelbine 35 mg/m2 intravenously on day 1 in an outpatient setting and G-CSF 10 μg/kg/day from day 4 divided in two daily doses. Median CD34+ cell blood counts measured on day 8 of mobilization were 142×106/l (range 57–467). One 15-l apheresis on day 8 resulted in sufficient stem cells (median 11.1×106 CD34+ cells/kg, range 6.2–36.0 prior and median 7.5×106 CD34+ cells/kg, range 4.0–20.2 postpositive CD34+ cell selection) for transplantation. Hematopoietic recovery was swift with ANC >0.5×109/l on day 11 median (range 10–15) and platelets >20×109/l on day 12 median (range 10–15) after reinfusion of the stem cells on day 0. No episodes of febrile neutropenia were observed during mobilization. In our institutions cost reduction for the procedure was about 1700 euros compared to the mobilization with cyclophosphamide and G-CSF. Vinorelbine and G-CSF allow precise timing and harvesting of sufficient stem cells, and might be an alternative to cyclophosphamide in the mobilization of stem cells for autologous transplantation in multiple myeloma.Keywords
This publication has 11 references indexed in Scilit:
- Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphomaBone Marrow Transplantation, 2001
- Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalitiesBlood, 2000
- Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cellsPREPARED BY THE CD34+ HAEMATOPOIETIC STEM CELL WORKING PARTY*Clinical and Laboratory Haematology, 1999
- Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.Journal of Clinical Oncology, 1998
- Estimation of the Progenitor Cell Yield in a Leukapheresis Product by Previous Measurement of CD34+ Cells in the Peripheral BloodVox Sanguinis, 1996
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myelomaBlood, 1995
- High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patientsBlood, 1993
- High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myelomaBlood, 1987
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975